Expanding Trial Access
Cancer is blind to age, race, economic background, and national borders. That's why inclusion is a hallmark of SWOG. Group leaders throughout history have made expanding clinical trial access a priority, so as many people as possible have access to cutting-edge cancer treatments.
In the 1990s, under Group Chair Dr. Charles Coltman Jr., SWOG actively recruited more women and minorities into trials, welcomed several new member institutions with a majority population of minority cancer patients, and forged research relationships with historically black colleges and universities. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), launched in 2001, enrolled an astonishing 35,533 men - 21 percent men of color - in just 33 months. This makes SELECT one of the most diverse cancer prevention trials ever completed.
"A lot of them...we couldn't send a letter to their homes because their homes were no longer there."